Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies

(2020) Eberhard Standl et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial

(2020) Matthew J. Crowley et al.   DIABETES CARE

Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States

(2019) Kristina S. Boye et al.   DIABETES OBESITY & METABOLISM

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2019) Mansoor Husain et al.   NEW ENGLAND JOURNAL OF MEDICINE

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETES CARE

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?

(2019) Silvio E. Inzucchi et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

(2018) Manfredi Rizzo et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

(2018) Andrei C. Sposito et al.   Cardiovascular Diabetology

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

(2018) Adrian F Hernandez et al.   LANCET

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

(2017) Aidin Rawshani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

(2015) Ele Ferrannini et al.   EUROPEAN HEART JOURNAL

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION